BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
BioStem Technologies Expands Product Access in Medicaid
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters